Small-sample confidence sets for the MTD in a phase I clinical trial
- PMID: 8117905
Small-sample confidence sets for the MTD in a phase I clinical trial
Abstract
Properties of procedures for interval estimation of the maximum tolerable dose (MTD) in a Phase I clinical trial are examined, using a two-stage stochastic sampling scheme (Storer, 1989) as a paradigm for development. Although the likelihood function for the data arising from such a scheme is identical to one arising under a conditional binomial sampling assumption, intervals based on the exact distribution of the usual large-sample statistics under this assumption do not offer improvement over unadjusted intervals. However, consideration of the distribution of these statistics based on the true stochastic sampling scheme can lead to the construction of intervals with correct coverage probabilities that do not depend on the true values of the model parameters. Membership in the confidence set can be evaluated by Monte Carlo simulation at a restricted maximum likelihood estimate of the nuisance slope parameter, despite upward bias in its estimation from the up-and-down sampling scheme. The lack of information in the small-sample setting is reflected in a large proportion of confidence intervals that include infinite values for the MTD, especially when the dose-response curve is shallow. Intervals based on a likelihood ratio criterion perform best in this regard.
Similar articles
-
Design and analysis of phase I clinical trials.Biometrics. 1989 Sep;45(3):925-37. Biometrics. 1989. PMID: 2790129
-
A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682. Stat Med. 2009. PMID: 19672839
-
Interval estimation of the proportion ratio under multiple matching.Stat Med. 2005 Apr 30;24(8):1275-85. doi: 10.1002/sim.1989. Stat Med. 2005. PMID: 15565736
-
Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness.Biometrics. 1988 Jun;44(2):323-38. Biometrics. 1988. PMID: 3291957 Review.
-
Interval estimation of risk ratio in the simple compliance randomized trial.Contemp Clin Trials. 2007 Feb;28(2):120-9. doi: 10.1016/j.cct.2006.05.005. Epub 2006 Jul 3. Contemp Clin Trials. 2007. PMID: 16820329 Review.
Cited by
-
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.Haematologica. 2020 Jun;105(6):1731-1737. doi: 10.3324/haematol.2019.229492. Epub 2019 Oct 3. Haematologica. 2020. PMID: 31582553 Free PMC article.
-
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.Clin Cancer Res. 2024 Jan 17;30(2):274-282. doi: 10.1158/1078-0432.CCR-23-1200. Clin Cancer Res. 2024. PMID: 37939122 Free PMC article. Clinical Trial.
-
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.Biol Blood Marrow Transplant. 2014 Sep;20(9):1363-8. doi: 10.1016/j.bbmt.2014.05.014. Epub 2014 May 20. Biol Blood Marrow Transplant. 2014. PMID: 24858425 Free PMC article.
-
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Blood. 2009 Dec 24;114(27):5444-53. doi: 10.1182/blood-2009-03-213298. Epub 2009 Sep 28. Blood. 2009. PMID: 19786617 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources